Conversion: SI to traditional units-K+: 1 mmol/l = 1 mEq/l. Mg++: 1 mmol/1=2 mEq/l. Ca++: 1 mmol/l =2 mEq/l. Sugar: 1 mmol/l 18 mg/100 ml. Urea: 1 mmol/ 6 mg/100 ml.
Clinical series
Grand mal seizures occurred in four patients being prepared for chemotherapy (table). All were adults with disseminated malignancy being treated with regimens containing cisplatin. The preparation schedule included saline and frusemide diuresis (2 1 physiological saline, 20 mmol(mEq) potassium, and 20 mg frusemide given over two to three hours before infusion of chemotherapeutic agents) and prophylactic antiemetic treatment with high dose domperidone. Domperidone was given in a dose of 0-6-1-8 mg/kg and administered as a slow intravenous infusion of 0-8-2-0 mg/ min. Serum electrolyte, blood sugar, calcium, and magnesium concentrations were monitored before chemotherapy and daily while receiving treatment.
Three patients (cases 1, 2, and 4) had previously received one to three courses of chemotherapy together with lower doses (0.4-1.0 mg/kg) of domperidone without having suffered seizures. These three patients had seizures on the second day of treatment cycles 2, 3, and 4 respectively. In all three instances the seizures occurred while domperidone was being infused and before administration of chemotherapy. All three patients continued to receive cisplatin based chemotherapy, but without pretreatment with domperidone and without recurrence of seizures. Investigations including computed tomography and electrolyte and blood sugar estimations (table) failed to show an alternative cause for the seizures. The remaining patient (case 3) was due to receive the cisplatin and methotrexate regimen but had a seizure while domperidone was being administered. The seizure was followed by cardiac and respiratory arrest. During attempted resuscitation ventricular tachycardia and fibrillation with large amplitude waves were observed in the electrocardiogram. Despite a 300 joule transthoracic shock irreversible asystole occurred.
Comment
The control of nausea and vomiting is an important component of chemotherapeutic practice, particularly with the rapidly expanding use of effective but intensely nauseating chemotherapeutic drugs.' Domperidone, a new benzimidazole derivative, has been reported to be very effective for the control of chemotherapy induced nausea and vomiting.2 The drug is believed to exert its antiemetic effect peripherally at the level of the dopamine receptors in the chemoreceptor trigger zone,4 and side effects in the central nervous system are reportedly rare when doses of 0-5-1 0 mg/kg are used.2 Domperidone also has a direct effect on the gut which may be mediated by inhibition of a specific subset of dopaminergic vagus nerve fibres.4
The occurrence of epileptic seizures in patients given domperidone has not previously been reported and several factors which may have been responsible in our patients were considered. When compared with other reports the amounts given did not appear to have been excessive either in total quantity or in rate of administration. Other factors which may have contributed were also examined. Electrolyte changes, particularly hypomagnesaemia and hypocalcaemia, may be induced by cisplatin. Although electrolyte abnormalities were detected in some of our patients, none of the changes appeared severe enough to cause seizures. Epileptic seizures have been described in patients treated with cisplatin5 but in our case 3 the patient developed seizures while receiving only intravenous fluids and antiemetic treatment and before receiving any chemotherapy whatsoever. That 
